News Briefing channel feed – Endpoints News

News Briefing channel feed

23andMe finds a buyer for its IL-36 bispecific in Almirall; Neurocrine, Idorsia revise epilepsy drug deal

6 years ago

Schrödinger adds another Big Pharma partner; Grey Wolf bags $3.3M to 'illuminate' tumors

6 years ago

Xencor, Verastem ink new deals; Scynexis' lead drug scores again

6 years ago

Rhythm CEO Keith Gottesdiener hits the exit; Takeda sets up an AI discovery program at MIT

6 years ago

Phathom Pharmaceuticals snatches up another Celgene exec; True North bets $74M for a stake in Biocon Biologics

6 years ago

Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs

6 years ago

Pfizer inks a back-ended $250M deal for skin-targeted JAK, pays $25M to set up the next leg of their hemophilia A R&D journey — while BioMarin jockeys for first OK

6 years ago

Biogen hands over $45M cash to license a tau project for Alzheimer's; Novartis launches a lottery for free dose of the world's priciest drug

6 years ago

Boehringer dumps its $250M NASH drug; Bavarian Nordic sells PRV for $95M; GBT inks deal with Syros, gets $150M loan

6 years ago

ImmunoGen maps new path to accelerated approval; BioNTech scores €50M funding from European bank

6 years ago

Charles River Labs forks over $380M cash for cell therapy player; Axsome soars on PhIII depression readout

6 years ago

More questions than answers for biopharma after UK election; Intercept gets FDA advisory date, and a PDUFA delay

6 years ago

Evenity finally wins EU approval; US-China biologics CDMO raises $60M

6 years ago

Stefan Fraenkel takes over as chief of Inceptua Group; Christi Shaw has a plan to make Yescarta safer

6 years ago

AstraZeneca teams up with Deep Matter for AI drug development; Cancer biotech ImmunOs raises $15M

6 years ago

Early-stage cancer biotech nails $85M C round; Flemming Ornskov's Galderma scores 'breakthrough' status

6 years ago

Antibiotic developer scores $50M from biotech billionaire; Biohaven's Alzheimer's drug passes futility test

6 years ago

AstraZeneca, Merck score China OK for Lynparza; Regeneron spotlights mid-stage data for rare disease drug

6 years ago

FDA will convene adcomm for Bristol-Myers' Reblozyl in MDS; FDA grants 'orphan' tags to a trio of drugs

6 years ago

AbbVie picks first Alzheimer's, Parkinson's targets in Mission pact; Amarin files for Vascepa OK in Europe

6 years ago

Incyte nabs priority review for bile duct cancer drug; Temasek shows interest in another Woodford darling — report

6 years ago

Merck adds another OK to Keytruda scoreboard; Ardelyx, Kyowa Kirin broadens partnership beyond tenapanor

6 years ago

Shares of Adamis crater on CRL; Boris Johnson promises to double dementia research funding

6 years ago

Japanese biotech pitching iPSC-derived med for the heart gains $26M; Andreessen Horowitz leads $4.1M seed funding for AI upstart

6 years ago

First page Previous page 43 44 454647 48 49 Next page Last page